Researchers reported that virus-like particles can enable efficient targeted gene engineering and pooled CRISPR screening in primary human myeloid cells, with the work published in Nature Biotechnology. The approach focuses on editing primary immune cells that are typically difficult to transfect or scale using standard CRISPR delivery. The publication describes virus-like particle delivery as a mechanism to reach functional editing in these cell types and supports pooled screens that can interrogate gene dependencies across conditions. (CRISPR pooled screening uses a library of guide RNAs in a mixed population to identify genes that change a measurable phenotype.) For translational immunology and early discovery, improved editing in myeloid cells can accelerate target validation, particularly for pathways implicated in inflammation, infection responses, and immune evasion. The ability to run pooled screens in primary cells also reduces reliance on immortalized lines that can diverge from patient-relevant biology. As this delivery method matures, the key industry question will be how reproducible editing efficiency and screen sensitivity are across donor variability and different myeloid subsets.